Core Viewpoint - Longsoft Technology is transitioning its customer procurement model from an authorization system to a subscription-based model, which is characterized by gradual implementation [2] Group 1: Business Strategy - The company is enhancing the brand promotion and market penetration of its "GIS+CAD" cloud platform through various initiatives, including recruiting partners nationwide, donating educational products to mining colleges, and organizing technical training and industry skill competitions [2] - In 2025, the company plans to sign exclusive regional cooperation agreements with the first ten core agents from multiple provincial administrative regions in China under the subscription model [2] - This cooperation highlights Longsoft's technological leadership in the mining sector and validates the market acceptance and commercial viability of its "Industrial Mapping + Spatiotemporal Intelligence" integrated products [2] Group 2: Future Plans - The company aims to strengthen its promotional matrix and operations by creating a professional, scenario-based, and diversified content ecosystem to explore the technical advantages and application value of its "GIS+CAD" cloud platform [2] - Longsoft intends to deepen collaboration with partners and actively expand into diverse application scenarios such as smart cities, renewable energy, construction engineering, and water and electricity sectors, thereby extending its industrial layout and building an open and win-win product ecosystem [2]

Financial Performance - In 2024, the company achieved a revenue of 40.033 billion CNY, a year-on-year increase of 2.36% [2] - The net profit attributable to shareholders reached 4.749 billion CNY, up 16.02% from 4.094 billion CNY in the previous year [2] - The net profit excluding non-recurring items was 4.523 billion CNY, reflecting a 20.18% increase from 3.764 billion CNY [2] - Operating cash flow net amount was 4.297 billion CNY, a growth of 22.68% [3] - The weighted average return on equity was 11.99%, an increase of 1.48 percentage points [3] - Basic earnings per share were 2.66 CNY, up 16.16% year-on-year [2] Business Structure and Efficiency - Industrial revenue accounted for 36.14% of total revenue, with an industrial revenue growth rate of 5.30% [3] - The gross margin for industrial products was 65.93%, an increase of 1.69 percentage points [3] - Sales expenses decreased by 2.26% and management expenses decreased by 1.98% compared to the previous year [3] - Total assets at the end of the reporting period were 52.914 billion CNY, with net assets attributable to shareholders at 38.832 billion CNY and a debt-to-asset ratio of 26.55% [3] Dividend Distribution - The company distributed a cash dividend of 11.85 CNY per 10 shares (before tax) based on a total share capital of 1,784,262,603 shares [4] - A special dividend of 12.13 CNY per 10 shares (before tax) was completed in November 2024, totaling 2.164 billion CNY [4] - The total cash dividend for 2024 was 23.98 CNY per 10 shares, amounting to 4.279 billion CNY, which represents 90.09% of the net profit attributable to shareholders [4] Pharmaceutical Business Highlights - The pharmaceutical segment focused on pain management and launched a new pain management model [5] - Clinical research on core products showed steady progress in areas like diabetic foot and skeletal pain [6] - Marketing initiatives included the successful promotion of a sports IP to enhance brand youthfulness [6] - The production efficiency was improved through the establishment of an online business process [6] Health Products and Channel Development - The health products segment maintained a leading market share in toothpaste and high brand penetration in oral care [7] - The company optimized its channel strategy, strengthening traditional channels while exploring new retail formats [8] Provincial Pharmaceutical Company Performance - In 2024, the provincial pharmaceutical company achieved a revenue of 24.607 billion CNY, a year-on-year increase of 0.48% [9] - Non-pharmaceutical business segments like medical devices and special medical foods saw a sales growth of 14% [9] - The OTC segment experienced an 18% sales increase, while the new specialty drug pharmacies grew by 29% [9] - Future plans include enhancing customer health services and integrating upstream and downstream resources [10]